GEN Exclusives

More »

GEN Webinars

More ยป

GEN Presents An Educational And Informative Webinar

Employing Open Access LC/MS In Support of Recombinant Protein Drug Development

  • Broadcast Date: Thursday, September 26, 2013
  • Time: 11 AM ET



Intact protein mass spectrometry is an important tool in the production and characterization of recombinant proteins. It is a primary quality control criterion and provides important information about the post-translational modification of protein samples. It can also be used to support drug development in characterizing compound-protein interactions or protein enzymatic activities in vitro. The Open Access approach increases the usability and productivity of the method by better controlling and automating data acquisition and analysis, and by reducing demands on skilled analysts. Peptide tandem mass spectrometry adds important capabilities including protein identification and site specific analysis of post-translational modifications, and can effectively coexist with intact protein LC-MS under the Open Access framework.

This webinar will discuss how Novartis has deployed an open access LC/MS platform for biochemists and biologists to analyze their own recombinant proteins

What You Will Learn

  • Common methods used to confirm protein identity and modifications
  • LC/MS Protein open access platform, workflows, user interface and reporting
  • Administration requirements of recombinant protein LC/MS open access
  • Benefits of deploying an open access platform within a recombinant protein group

Who Should Attend

  • Protein analytical scientists who currently support recombinant protein discovery and development groups
  • Biochemists and biologists who express recombinant proteins and are wanting to use LC/MS to confirm protein identity and modifications
  • Bioprocess engineers and quality control professionals who are considering the use of LC/MS in a manufacturing setting

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.



  • Eric Fang,
  • Scientist
  • Protein Sciences
  • Novartis
  • Gurmil Gendeh, Ph.D,
  • Senior Segment Market Manager
  • Biopharma and Biosimilars
  • Agilent


  • Tamlyn Oliver
  • Managing Editor
  • Genetic Engineering & Biotechnology News

Produced with support from